PHX — Pharmx Technologies Share Price
0.000.00%
Last trade - 00:00- AU$28.13m
- AU$15.23m
- AU$6.78m
- 80
- 60
- 88
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.76 | ||
| Price to Tang. Book | 9.25 | ||
| Price to Free Cashflow | 17.33 | ||
| Price to Sales | 4.15 | ||
| EV to EBITDA | 10.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.36% | ||
| Return on Equity | 0.5% | ||
| Operating Margin | 3.6% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 10.64 | 11.88 | 5.38 | 6.13 | 6.78 | n/a | n/a | -9.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -36.25 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmX Technologies Limited, formerly Corum Group Limited, is an Australian company that operates a network connecting retail pharmacies and suppliers in Australia and New Zealand. The Company offers PharmX, an electronic gateway that links pharmacies, pharmaceutical wholesalers and direct suppliers within the pharmacy market, and PharmXchange, a digital sales and marketing platform integrated with PharmX. The Company is also focused on creating a more productive environment for pharmacy and suppliers, with additional ordering functions, such as stock checks, credits, and auto account set up direct from their point of sale (POS) system.
Directors
- Nick England CHM
- David Castles GMG
- Geoffrey Arnold OTH
- Vinit Kumar OTH
- Claude Matthews OTH
- Eryl Baron SEC
- Dennis Bastas DRC
- Andrew Jonathan George Newbery DRC
- Jayne Shaw DRC
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- December 11th, 1950
- Public Since
- July 28th, 1971
- No. of Shareholders
- 1,795
- No. of Employees
- 109
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 598,506,789
- Address
- Level 3, 120 Sussex Street, SYDNEY, 2000
- Web
- https://www.corumgroup.com.au/
- Phone
- +61 292894699
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for PHX
Half Year 2025 Pharmx Technologies Ltd Earnings Release
Similar to PHX
3P Learning
Australian Stock Exchange - SEATS
5G Networks
Australian Stock Exchange - SEATS
8Common
Australian Stock Exchange - SEATS
ActivePort
Australian Stock Exchange - SEATS
AD1 Holdings
Australian Stock Exchange - SEATS
FAQ
What is the Pharmx Technologies share price?
As of Today at 22:38 UTC, shares in Pharmx Technologies are trading at AU$0.05. This share price information is delayed by 15 minutes.
How has the Pharmx Technologies share price performed this year?
Shares in Pharmx Technologies last closed at AU$0.05 and the price had moved by +29.06% over the past 365 days. In terms of relative price strength the Pharmx Technologies share price has outperformed the ASX All Ordinaries Index by +9.37% over the past year.
What are the analyst and broker recommendations for Pharmx Technologies?
The overall consensus recommendation for Pharmx Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharmx Technologies dividend yield?
Pharmx Technologies does not currently pay a dividend.
Does Pharmx Technologies pay a dividend?
Pharmx Technologies does not currently pay a dividend.
When does Pharmx Technologies next pay dividends?
Pharmx Technologies does not currently pay a dividend.
How do I buy Pharmx Technologies shares?
To buy shares in Pharmx Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmx Technologies?
As of the previous close price of AU$0.05, shares in Pharmx Technologies had a market capitalisation of AU$28.13m.
Where are Pharmx Technologies shares listed?
Here are the trading details for Pharmx Technologies:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PHX
What kind of share is Pharmx Technologies?
Based on an overall assessment of its quality, value and momentum Pharmx Technologies is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmx Technologies share price forecast for 2024?
The analyst consensus target price for shares in Pharmx Technologies is AU$0.13. That is 176.6% above the last closing price of AU$0.05.
Analysts covering Pharmx Technologies currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Pharmx Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmx Technologies. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +38.19%.
As of the last closing price of AU$0.05, shares in Pharmx Technologies were trading +23.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmx Technologies PE Ratio?
The Pharmx Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmx Technologies?
Pharmx Technologies' management team is headed by:
- Nick England - CHM
- David Castles - GMG
- Geoffrey Arnold - OTH
- Vinit Kumar - OTH
- Claude Matthews - OTH
- Eryl Baron - SEC
- Dennis Bastas - DRC
- Andrew Jonathan George Newbery - DRC
- Jayne Shaw - DRC